The role of bisphosphonates in the adjuvant setting for breast cancer

ONCOLOGY

Volumn 24, Issue 6, 2010, Pages

  Reeder, Jennifer G ^a   Brufsky, Adam M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DENOSUMAB; ESTRADIOL; ESTROGEN; FLUOROURACIL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; IBANDRONIC ACID; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; PLACEBO; PROLIA; RISEDRONIC ACID; TAMOXIFEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BONE ATROPHY; BONE DENSITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CANCER TREATMENT INDUCED BONE LOSS; CHRONIC PAIN; CLINICAL TRIAL; DRUG FEVER; DRUG INDUCED DISEASE; DRUG INTERMITTENT THERAPY; FLU LIKE SYNDROME; FRACTURE; FRAGILITY FRACTURE; HUMAN; JAW OSTEONECROSIS; KIDNEY FAILURE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; OSTEOPENIA; OSTEOPOROSIS; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PATHOGENESIS; PATIENT MOBILITY; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 77954147840     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Early Breast Cancer Trialists Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 365:1687-1717, 2005.
2. Pfeilschifter J, Diel IJ: Osteoporosis due to cancer treatment: Pathogenesis and management. J Clin Oncol 18:1570-1593, 2000. (Pubitemid 30205404)
3. Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306-3311, 2001. (Pubitemid 32642182)
4. Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729, 1996. (Pubitemid 26134232)
5. Kanis JA, Oden A, Johnell O, et al: The components of excess mortality after hip fracture. Bone 32:468-473, 2003. (Pubitemid 39665705)
6. Seeger H, Hadji P, Mueck AO: Endogenous estradiol metabolites stimulate the in vitro proliferation of human osteoblastic cells. Int J Clin Pharmacol Ther 41:148-152, 2003. (Pubitemid 36443255)
7. Seeman E, Delmas PD:. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 354:2250, 2006. (Pubitemid 43788139)
8. Eastell R, Hannon RA, Cuzick J, et al: Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215-1223, 2006. (Pubitemid 44128334)
9. Baum M, Buzdar A, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802-1810, 2003.
10. Perez EA, Josse RG, Pritchard KI, et al: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 24:3629-3635, 2006.
11. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003.
12. Saarto T, Blomqvist C, Valimaki M, et al: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341-1347, 1997. (Pubitemid 27167365)
13. Delmas PD, Balena R, Confravreux E, et al: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. J Clin Oncol 15:955-962, 1997. (Pubitemid 27106277)
14. Saarto T, Vehmanen L, Blomqvist C, et al: Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 26:4289-4295, 2008.
15. Greenspan SL, Brufsky A, Lembersky PC, et al: Risedronate prevents bone loss in breast cancer survivors: A 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 26:2644-2652, 2008.
16. Kohno N, Aogi K, Minami H, et al: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol 23:3314-3321, 2005. (Pubitemid 46243475)
17. Rosen LS, Gordon D, Tchekmedyian NS, et al: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer 100:2613-2621, 2004.
18. Saad F, Gleason DM, Murray R, et al: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879-882, 2004. (Pubitemid 38807610)
19. Rosen LS, Gordon D, Kaminski M, et al: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial. Cancer 98:1735-1744, 2003.
20. Pavlakis N, Schmidt RL, Stockler M: Bisphosphonates for breast cancer (review). Cochrane Database Syst Rev Jul 20(3):CD003474, 2005.
21. Hershman DL, McMahon DJ, Crew KD, et al: Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26:4739-4745, 2008.
22. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al: Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 25:820-828, 2007.
23. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al: Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840-849, 2008.
24. Shapiro CL, Halabi S, Gibson G, et al: Effect of zoledronic acid on bone mineral density (BMD) in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: First results from CALGB trial 79809 (abstract 512). J Clin Oncol 26:2008.
25. Brufsky A, Harker WG, Beck JT, et al: Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836, 2007.
26. Brufsky A, Bundred N, Coleman R, et al: Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13:503-514, 2008. (Pubitemid 351872868)
27. Ellis GK, Bone HG, Chlebowski RT, et al: Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26:4875-4882, 2008.
28. Winter MC, Holen I, Coleman RE: Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:452-475, 2008.
29. Mundy GR: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584-593, 2002.
30. Powles T, Paterson A, McCloskey E, et al: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] [published correction appears in Breast Cancer Res 2006; 6:804]. Breast Cancer Res 8:R13, 2006.
31. Diel IJ, Jaschke A, Solamayer EF, et al: Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: A long-term follow-up. Ann Oncol 19:2007-2011, 2008.
32. Saarto T, Vehmanen L, Virkkunen P, et al: Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol 43:650-656, 2004.
33. Ha TC, Li H: Meta-anaylsis of clodronate and breast cancer survival. 96:1796-1801, Br J Cancer 2007.
34. Gnant M, Mlineritsch B, Schippinger W, et al: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679-691, 2009.
35. Frassoldati A, Brufsky A, Bundred N, et al: The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24-month integrated follow-up of the Z-FAST and ZO-FAST trials (abstract 185 PD). Presented at the 33rd Congress of the European Society for Medical Oncology, Stockholm, Sweden, September 12-16, 2008.
36. Brufsky AM, Bosserman LD, Caradonna RR, et al: Zoledronic acid effectively prevents aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 9:77-85, 2009.